Drug intelligence / Profile preview

paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of five anticancer drugs used in the treatment of cancer, particularly breast cancer. Each component has a distinct mechanism of action: - Paclitaxel (Taxol): A taxane that damages the structure supporting cancer cells, preventing cell division - Carboplatin: A platinum agent that damages DNA in cancer cells - Doxorubicin (Adriamycin): An anthracycline that damages DNA inside cancer cells - Cyclophosphamide (Cytoxan): An alkylating agent that damages DNA in cancer cells during their resting phase - Capecitabine (Xeloda): An oral prodrug that converts to 5-fluorouracil in tumor tissue This intensive combination would likely be used in advanced or high-risk cancer cases where aggressive treatment is warranted.

Other names: Sequential paclitaxel/carboplatin followed by doxorubicin/cyclophosphamide/capecitabineRAMS neoadjuvant TNBC regimenSequential Chemotherapy for Locally Advanced TNBC

Targets

TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + carboplatin + doxorubicin + cyclophosphamide + capecitabine.

Explore the full profile